Therefore, a subsequent phase-III trial was initiated in China to further explore these results in patients with CLDN18.2 positive, which is defined as ≥40% of tumor cells, advanced GET (NCT06206733) [137]. This evidence concerns the gene CLDN18 and neoplasm.